A pharmaceutical company engaged in research, development and manufacture of innovative Aversion(r) Technology and related product candidates.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Acura is up 15% today apparently because they were awarded a patent. Patents are a fairly common thing in biotech and small pharma, and in fact are a prerequisite for any attempt at commercialization of a product. So I'm not really surprised or impressed that Acura obtained a patent. What would impress me is if Acura is actually able to sell enough Oxecta or Impede PSE to justify their development costs. For reasons I've outlined in detail previously, I don't think they will. The dominant providers of opiate pain medications have no incentive to prescribe abuse-resistant products, barring legislation which has not even been proposed.